<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Rx Times Pharmacy Magazine</title>
	<atom:link href="http://www.rxtimes.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.rxtimes.com</link>
	<description>Pharmacy news, jobs, continuing education, community and more.</description>
	<lastBuildDate>Mon, 20 Feb 2012 03:14:39 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>FDA requests additional data on Novartis quadrivalent meningococcal conjugate vaccine, Menveo®, for expanded use in infants and toddlers</title>
		<link>http://www.rxtimes.com/fda-requests-additional-data-on-novartis-quadrivalent-meningococcal-conjugate-vaccine-menveo%c2%ae-for-expanded-use-in-infants-and-toddlers/</link>
		<comments>http://www.rxtimes.com/fda-requests-additional-data-on-novartis-quadrivalent-meningococcal-conjugate-vaccine-menveo%c2%ae-for-expanded-use-in-infants-and-toddlers/#comments</comments>
		<pubDate>Mon, 13 Feb 2012 22:57:46 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Features]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Menveo]]></category>
		<category><![CDATA[Novartis]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5721</guid>
		<description><![CDATA[Novartis has received a Complete Response letter from the US Food and Drug Administration (FDA) on its application for the expanded use of Menveo® (Meningococcal [Groups A, C, Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) in infants and toddlers from 2 months of age. Menveo is already approved for use in individuals 2 to [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/fda-requests-additional-data-on-novartis-quadrivalent-meningococcal-conjugate-vaccine-menveo%c2%ae-for-expanded-use-in-infants-and-toddlers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bristol-Myers Squibb Announces Successful Completion of Cash Tender Offer for Shares of Inhibitex, Inc.</title>
		<link>http://www.rxtimes.com/bristol-myers-squibb-announces-successful-completion-of-cash-tender-offer-for-shares-of-inhibitex-inc/</link>
		<comments>http://www.rxtimes.com/bristol-myers-squibb-announces-successful-completion-of-cash-tender-offer-for-shares-of-inhibitex-inc/#comments</comments>
		<pubDate>Mon, 13 Feb 2012 21:31:24 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Features]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[Inhibitex]]></category>
		<category><![CDATA[Mergers and Acquisitions]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5719</guid>
		<description><![CDATA[Bristol-Myers Squibb Company (NYSE: BMY) announced today the successful completion of the tender offer by Bristol-Myers Squibb Company (“Bristol-Myers”) for all of the outstanding shares of common stock of Inhibitex, Inc. (NASDAQ: INHX) (“Inhibitex”) at a purchase price of $26.00 per share. The tender offer expired at midnight, New York City time, on February 10, [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/bristol-myers-squibb-announces-successful-completion-of-cash-tender-offer-for-shares-of-inhibitex-inc/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer Issues Statement On Voluntary Recall</title>
		<link>http://www.rxtimes.com/pfizer-issues-statement-on-voluntary-recall/</link>
		<comments>http://www.rxtimes.com/pfizer-issues-statement-on-voluntary-recall/#comments</comments>
		<pubDate>Wed, 01 Feb 2012 21:14:13 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Features]]></category>
		<category><![CDATA[Drug Recall]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Lo/Ovral®-28]]></category>
		<category><![CDATA[Pfizer]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5715</guid>
		<description><![CDATA[Pfizer Inc. today issued the following statement regarding the voluntary recall of Lo/Ovral®-28 (norgestrel and ethinyl estradiol): “Upon discovery of the issue, we took corrective action and notified the FDA.” “We have announced a voluntary recall of Lo/Ovral®-28 (norgestrel and ethinyl estradiol) and Norgestrel and Ethinyl Estradiol Tablets (generic) birth control pills in the United [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/pfizer-issues-statement-on-voluntary-recall/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Novartis Consumer Health Inc. voluntarily recalls certain over-the-counter products</title>
		<link>http://www.rxtimes.com/novartis-consumer-health-inc-voluntarily-recalls-certain-over-the-counter-products/</link>
		<comments>http://www.rxtimes.com/novartis-consumer-health-inc-voluntarily-recalls-certain-over-the-counter-products/#comments</comments>
		<pubDate>Mon, 09 Jan 2012 03:44:42 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Features]]></category>
		<category><![CDATA[Bufferin®]]></category>
		<category><![CDATA[Excedrin®]]></category>
		<category><![CDATA[Gas-X Prevention®]]></category>
		<category><![CDATA[NoDoz®]]></category>
		<category><![CDATA[Novartis Consumer Health Inc.]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5687</guid>
		<description><![CDATA[Novartis Consumer Health Inc. (NCH) informed customers, that it is voluntarily recalling all lots of select bottle packaging configurations from retailers of Excedrin® and NoDoz® products with expiry dates of December 20, 2014 or earlier as well as Bufferin® and Gas-X Prevention® products with expiry dates of December 20, 2013 or earlier, in the United [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/novartis-consumer-health-inc-voluntarily-recalls-certain-over-the-counter-products/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>NARCO – VIOLENCE AT THE LOCAL PHARMACY</title>
		<link>http://www.rxtimes.com/narco-%e2%80%93-violence-at-the-local-pharmacy/</link>
		<comments>http://www.rxtimes.com/narco-%e2%80%93-violence-at-the-local-pharmacy/#comments</comments>
		<pubDate>Mon, 09 Jan 2012 03:21:35 +0000</pubDate>
		<dc:creator>Matt Murphy</dc:creator>
				<category><![CDATA[Features]]></category>
		<category><![CDATA[Oxycodone]]></category>
		<category><![CDATA[Pharmacy Robbery]]></category>
		<category><![CDATA[Pharmacy Violence]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5677</guid>
		<description><![CDATA[This past June in a tiny pharmacy in the sleepy suburban town of Medford, New York, a deranged gunman high on prescription drugs executed four innocent victims in cold blood. “In all of my law enforcement experience and in the experience of the police that are involved in this investigation, this is one of the [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/narco-%e2%80%93-violence-at-the-local-pharmacy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bristol-Myers Squibb to Acquire Inhibitex</title>
		<link>http://www.rxtimes.com/bristol-myers-squibb-to-acquire-inhibitex/</link>
		<comments>http://www.rxtimes.com/bristol-myers-squibb-to-acquire-inhibitex/#comments</comments>
		<pubDate>Sun, 08 Jan 2012 03:28:36 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Features]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[Inhibitex]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5682</guid>
		<description><![CDATA[Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction, with an aggregate purchase price of approximately $2.5 billion, has been approved [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/bristol-myers-squibb-to-acquire-inhibitex/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer Completes Acquisition of Excaliard</title>
		<link>http://www.rxtimes.com/pfizer-completes-acquisition-of-excaliard/</link>
		<comments>http://www.rxtimes.com/pfizer-completes-acquisition-of-excaliard/#comments</comments>
		<pubDate>Fri, 02 Dec 2011 23:37:23 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Features]]></category>
		<category><![CDATA[Acquisition]]></category>
		<category><![CDATA[Excaliard]]></category>
		<category><![CDATA[Excaliard Pharmaceuticals]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[Pfizer]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5657</guid>
		<description><![CDATA[Pfizer Inc. (NYSE: PFE) announced today that it has completed its acquisition of Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. “It is imperative at Pfizer that we continue to develop new and innovative treatments to address [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/pfizer-completes-acquisition-of-excaliard/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Eli Lilly and Company Named a Top Global Company for Leaders</title>
		<link>http://www.rxtimes.com/eli-lilly-and-company-named-a-top-global-company-for-leaders/</link>
		<comments>http://www.rxtimes.com/eli-lilly-and-company-named-a-top-global-company-for-leaders/#comments</comments>
		<pubDate>Thu, 01 Dec 2011 23:34:36 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Features]]></category>
		<category><![CDATA[Eli Lilly and Company]]></category>
		<category><![CDATA[top 25 global companies for leaders]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5655</guid>
		<description><![CDATA[Eli Lilly and Company (NYSE: LLY) has been named one of the top 25 global companies for leaders by Aon Hewitt in partnership with FORTUNE and the RBL Group. Lilly ranked 16th on the Global 25 list and 12th on the North American list. The survey is one of the most comprehensive studies of talent [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/eli-lilly-and-company-named-a-top-global-company-for-leaders/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Lilly Announces First and Only International, Prospective Observational Study Designed to Understand Barriers to Progression of Insulin Treatment</title>
		<link>http://www.rxtimes.com/lilly-announces-first-and-only-international-prospective-observational-study-designed-to-understand-barriers-to-progression-of-insulin-treatment/</link>
		<comments>http://www.rxtimes.com/lilly-announces-first-and-only-international-prospective-observational-study-designed-to-understand-barriers-to-progression-of-insulin-treatment/#comments</comments>
		<pubDate>Thu, 01 Dec 2011 23:32:07 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Features]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[Eli Lilly and Company]]></category>
		<category><![CDATA[insulin]]></category>
		<category><![CDATA[MOSA1c]]></category>
		<category><![CDATA[Type 2 Diabetes]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5653</guid>
		<description><![CDATA[Eli Lilly and Company (NYSE: LLY) today announced it is conducting the first major international, prospective observational study designed to understand the real-world obstacles that people with type 2 diabetes face that prevent them from reaching their ultimate treatment goals. Many people with diabetes who take daily insulin resist a progression of insulin therapy that [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/lilly-announces-first-and-only-international-prospective-observational-study-designed-to-understand-barriers-to-progression-of-insulin-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Provides Clearance for New Test to Detect Vitamin D Levels</title>
		<link>http://www.rxtimes.com/fda-provides-clearance-for-new-test-to-detect-vitamin-d-levels/</link>
		<comments>http://www.rxtimes.com/fda-provides-clearance-for-new-test-to-detect-vitamin-d-levels/#comments</comments>
		<pubDate>Wed, 30 Nov 2011 23:19:08 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Features]]></category>
		<category><![CDATA[Abbott]]></category>
		<category><![CDATA[Vitamin D]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5649</guid>
		<description><![CDATA[Abbott (NYSE: ABT) announced today it has received clearance from the U.S. Food and Drug Administration for a fully-automated 25-OH Vitamin D assay performed on its widely used ARCHITECT®laboratory testing platform. Published data from the Third National Health and Nutrition Survey, reported in the Archives of Internal Medicine, show that less than a quarter of [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/fda-provides-clearance-for-new-test-to-detect-vitamin-d-levels/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

